Tiziana Life Sciences
TLSA

$1.11

3.4%

Market Cap: $112M

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Employees: 9

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

98% more capital invested

Capital invested by funds: $431K [Q1] → $854K (+$423K) [Q2]

35% more funds holding

Funds holding: 20 [Q1] → 27 (+7) [Q2]

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0.02% less ownership

Funds ownership: 0.92% [Q1] → 0.91% (-0.02%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for TLSA.

See Analyst Rankings

Financial journalist opinion

Proactive Investors

Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.

Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research

Proactive Investors

Tiziana Life Sciences names new chief executive

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. The company highlighted that Elfiri previously served as the global head of the Patent Group at Cooley since 2014, and before that, he led the Patents division at Mintz Levin from 1999 to 2014.

Tiziana Life Sciences names new chief executive

Tiziana Life Sciences Appoints New Chief Executive Officer

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately.

Tiziana Life Sciences Appoints New Chief Executive Officer

Proactive Investors

Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formulation of foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis. The FDA's Fast Track designation is intended to support the development of and review of drugs that address an unmet medical need.

Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab

Tiziana Life Sciences Granted FDA Fast Track Designation

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its intranasal formulation of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

Tiziana Life Sciences Granted FDA Fast Track Designation

Proactive Investors

Tiziana Life Sciences secures $3.4M in non-dilutive funding

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.

Tiziana Life Sciences secures $3.4M in non-dilutive funding

Tiziana Receives $3.4 Million in Non-Dilutive Funding

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Proactive Investors

Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.

Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease.

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

Proactive Investors

Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatment

Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab, a fully human anti-CD3 monoclonal antibody, has demonstrated the ability to induce T regulatory cell production when administered intranasally.

Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatment

See News Rankings